Oryzon Genomics - Positive safety data for vafidemstat in PORTICO
Oryzon has announced positive aggregate safety data for vafidemstat, which is being evaluated in the ongoing PORTICO trial as a potential treatment...
287 Views
Oryzon Genomics - Advancing on multiple clinical fronts in Q1
Oryzon has reported Q123 results highlighting its near-term strategic priorities, including a favourable interim analysis of its lead asset study,...
231 Views
Oryzon Genomics - Promising PORTICO interim results
Oryzon has announced promising results from an interim analysis of the Phase IIb PORTICO study, a trial evaluating vafidemstat as a treatment for...
274 Views
Oryzon Genomics - Clinical milestone reached with FRIDA initiation
Oryzon Genomics has announced it has enrolled the first patient in its Phase Ib FRIDA study investigating iadademstat in combination with Astellas’...
461 Views
Oryzon Genomics - New clinical candidate expands CNS portfolio
Oryzon Genomics has nominated a new central nervous system (CNS) clinical development candidate, ORY-4001, for the treatment of rare CNS disorders...
219 Views